Lyra Therapeutics, Inc. financial data

Symbol
LYRA on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
480 Arsenal Way, Watertown, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
480 Biomedical, Inc. (to 11/28/2016), Arsenal Vascular, Inc. (to 11/8/2011), Arsenal Medical, Inc. (to 8/12/2010), WMR Biomedical Inc (to 2/27/2009)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 480 % -35%
Debt-to-equity 77 % +136%
Return On Equity -144 % -99.9%
Return On Assets -81.2 % -49.8%
Operating Margin -5.81K % -12.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.5M shares +32.1%
Common Stock, Shares, Outstanding 65.5M shares +32.1%
Entity Public Float 143B USD +39.1%
Common Stock, Value, Issued 65K USD +30%
Weighted Average Number of Shares Outstanding, Basic 65.5M shares +49.9%
Weighted Average Number of Shares Outstanding, Diluted 65.5M shares +49.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.82M USD +47%
Research and Development Expense 56.1M USD +30.9%
General and Administrative Expense 20.3M USD +5.64%
Operating Income (Loss) -106M USD -65.8%
Nonoperating Income (Expense) 4.47M USD +50.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -101M USD -66.6%
Income Tax Expense (Benefit) 59K USD 0%
Net Income (Loss) Attributable to Parent -101M USD -66.6%
Earnings Per Share, Basic -1.55 USD/shares -20.2%
Earnings Per Share, Diluted -1.55 USD/shares -20.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.9M USD -41.3%
Assets, Current 69.4M USD -41.3%
Property, Plant and Equipment, Net 1.67M USD +197%
Operating Lease, Right-of-Use Asset 21.5M USD +1413%
Other Assets, Noncurrent 683K USD -82.3%
Assets 94.6M USD -24.7%
Accounts Payable, Current 4.97M USD +18.7%
Employee-related Liabilities, Current 4.67M USD +57%
Liabilities, Current 19.3M USD +36.6%
Operating Lease, Liability, Noncurrent 32.5M USD
Liabilities 63.6M USD +135%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD +85.2%
Retained Earnings (Accumulated Deficit) -382M USD -36.1%
Stockholders' Equity Attributable to Parent 31M USD -68.6%
Liabilities and Equity 94.6M USD -24.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.5M USD -41.7%
Net Cash Provided by (Used in) Financing Activities 8.64M USD +116%
Net Cash Provided by (Used in) Investing Activities 7.86M USD +47.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 65.5M shares +32.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.95M USD +43.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.9M USD -39.2%
Deferred Tax Assets, Valuation Allowance 60M USD +48%
Deferred Tax Assets, Gross 67.3M USD +63.9%
Operating Lease, Liability 36.7M USD
Depreciation 136K USD -52.1%
Payments to Acquire Property, Plant, and Equipment 2.15M USD +4676%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -101M USD -66.4%
Lessee, Operating Lease, Liability, to be Paid 46.4M USD
Property, Plant and Equipment, Gross 5.75M USD
Operating Lease, Liability, Current 4.27M USD +153%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.49M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.12M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -24.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.69M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.13M USD
Deferred Tax Assets, Operating Loss Carryforwards 30M USD +19.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.51M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.39M USD +1166%
Share-based Payment Arrangement, Expense 6.21M USD -3.89%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%